Jacques Vargaftig

1.8k total citations
23 papers, 887 citations indexed

About

Jacques Vargaftig is a scholar working on Hematology, Genetics and Pathology and Forensic Medicine. According to data from OpenAlex, Jacques Vargaftig has authored 23 papers receiving a total of 887 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Hematology, 11 papers in Genetics and 8 papers in Pathology and Forensic Medicine. Recurrent topics in Jacques Vargaftig's work include Acute Myeloid Leukemia Research (8 papers), Lymphoma Diagnosis and Treatment (7 papers) and Hematopoietic Stem Cell Transplantation (5 papers). Jacques Vargaftig is often cited by papers focused on Acute Myeloid Leukemia Research (8 papers), Lymphoma Diagnosis and Treatment (7 papers) and Hematopoietic Stem Cell Transplantation (5 papers). Jacques Vargaftig collaborates with scholars based in France, United Kingdom and Belgium. Jacques Vargaftig's co-authors include Dominique Bonnet, Emmanuel Griessinger, John G. Gribben, David Taussig, Tim Lister, Jamie Cavenagh, Heather Oakervee, Kirsty Sharrock, Debra M. Lillington and Farideh Miraki‐Moud and has published in prestigious journals such as Blood, Cancer Research and Clinical Infectious Diseases.

In The Last Decade

Jacques Vargaftig

23 papers receiving 880 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jacques Vargaftig France 12 439 309 249 208 202 23 887
Wendy Cuccuini France 13 301 0.7× 325 1.1× 217 0.9× 86 0.4× 316 1.6× 36 873
Marie Jarošová Czechia 17 354 0.8× 264 0.9× 301 1.2× 95 0.5× 156 0.8× 87 766
Alejandra Martínez‐Trillos Spain 16 207 0.5× 323 1.0× 514 2.1× 191 0.9× 419 2.1× 26 898
Claudiu Cotta United States 16 182 0.4× 294 1.0× 123 0.5× 126 0.6× 123 0.6× 50 638
Florence Armstrong France 10 180 0.4× 290 0.9× 82 0.3× 118 0.6× 129 0.6× 12 630
Aleksandra Rizo United States 10 337 0.8× 314 1.0× 215 0.9× 80 0.4× 147 0.7× 28 655
Takashi Akasaka Japan 15 92 0.2× 222 0.7× 229 0.9× 120 0.6× 323 1.6× 45 660
Beata Holkova United States 13 155 0.4× 222 0.7× 139 0.6× 87 0.4× 297 1.5× 48 634
Julia Steinhilber Germany 15 107 0.2× 144 0.5× 235 0.9× 132 0.6× 392 1.9× 28 652
K Longin United States 12 870 2.0× 113 0.4× 212 0.9× 251 1.2× 84 0.4× 18 1.1k

Countries citing papers authored by Jacques Vargaftig

Since Specialization
Citations

This map shows the geographic impact of Jacques Vargaftig's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jacques Vargaftig with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jacques Vargaftig more than expected).

Fields of papers citing papers by Jacques Vargaftig

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jacques Vargaftig. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jacques Vargaftig. The network helps show where Jacques Vargaftig may publish in the future.

Co-authorship network of co-authors of Jacques Vargaftig

This figure shows the co-authorship network connecting the top 25 collaborators of Jacques Vargaftig. A scholar is included among the top collaborators of Jacques Vargaftig based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jacques Vargaftig. Jacques Vargaftig is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Joseph, Adrien, Stéphanie Harel, Laurent Mesnard, et al.. (2024). Carfilzomib-associated thrombotic microangiopathy: clinical features and outcomes. Nephrology Dialysis Transplantation. 39(12). 2067–2078. 4 indexed citations
2.
Jaccard, Arnaud, Jean‐François Benoist, Lucile Couronné, et al.. (2018). Monitoring Asparaginase Activity in 21 Patients with Extranodal NK/T-Cell Lymphoma Shows a Very High Proportion of Asparaginase Inactivation. Blood. 132(Supplement 1). 5351–5351. 1 indexed citations
3.
Vargaftig, Jacques, H. Farhat, Lionel Adès, et al.. (2018). Phase 2 Trial of Single Agent Gedatolisib (PF-05212384), a Dual PI3K/mTOR Inhibitor, for Adverse Prognosis and Relapse/Refractory AML: Clinical and Transcriptomic Results. Blood. 132(Supplement 1). 5233–5233. 8 indexed citations
4.
Griessinger, Emmanuel, Jacques Vargaftig, Stuart Horswell, et al.. (2017). Acute myeloid leukemia xenograft success prediction: Saving time. Experimental Hematology. 59. 66–71.e4. 16 indexed citations
5.
Houillier, Caroline, Hervé Ghesquières, Cécile Moluçon‐Chabrot, et al.. (2017). Rituximab, methotrexate, procarbazine, vincristine and intensified cytarabine consolidation for primary central nervous system lymphoma (PCNSL) in the elderly: a LOC network study. Journal of Neuro-Oncology. 133(2). 315–320. 44 indexed citations
6.
Griessinger, Emmanuel, Fernando Anjos‐Afonso, Jacques Vargaftig, et al.. (2016). Frequency and Dynamics of Leukemia-Initiating Cells during Short-term Ex Vivo Culture Informs Outcomes in Acute Myeloid Leukemia Patients. Cancer Research. 76(8). 2082–2086. 19 indexed citations
7.
Costopoulos, Myrto, Marie‐Laure Tanguy, Caroline Houillier, et al.. (2016). The CSF IL-10 concentration is an effective diagnostic marker in immunocompetent primary CNS lymphoma and a potential prognostic biomarker in treatment-responsive patients. European Journal of Cancer. 61. 69–76. 68 indexed citations
8.
Souchet, Laëtitia, Vincent Lévy, Jérôme Tamburini, et al.. (2016). Efficacy and long‐term toxicity of the rituximab‐fludarabine‐cyclophosphamide combination therapy in Waldenstrom's macroglobulinemia. American Journal of Hematology. 91(8). 782–786. 24 indexed citations
9.
Bennani, H., Raphaël Coscas, Marc Coggia, et al.. (2015). Acute Common Iliac Artery Thrombosis with Concurrent Pulmonary Embolism Revealing AML M2: Role of Elevated Plasma Tissue Factor Activity. Blood. 126(23). 4722–4722. 1 indexed citations
10.
11.
12.
Quintana-Bustamante, Óscar, Emmanuel Griessinger, Yasmin Reyal, et al.. (2012). Overexpression of wild-type or mutants forms of CEBPA alter normal human hematopoiesis. Leukemia. 26(7). 1537–1546. 17 indexed citations
13.
Kuranda, Klaudia, Jacques Vargaftig, Philippe De La Rochère, et al.. (2011). Age-related changes in human hematopoietic stem/progenitor cells. Aging Cell. 10(3). 542–546. 124 indexed citations
14.
Gandillet, Arnaud, Sophie Park, François Lassailly, et al.. (2011). Heterogeneous sensitivity of human acute myeloid leukemia to β-catenin down-modulation. Leukemia. 25(5). 770–780. 44 indexed citations
15.
Taussig, David, Jacques Vargaftig, Farideh Miraki‐Moud, et al.. (2010). Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34− fraction. Blood. 115(10). 1976–1984. 262 indexed citations
16.
Vargaftig, Jacques, et al.. (2007). [Bilateral and recurrent facial palsy due to lymphoma: a case report].. PubMed. 128(1-2). 69–72. 2 indexed citations
17.
Vargaftig, Jacques, Beatrice Mahé, Steven Le Gouill, et al.. (2006). Fludarabine Plus Cyclophosphamide and Rituximab (RFC) in Waldenstrom’s Macroglobulinemia (WM): Results in 21 Patients (pts).. Blood. 108(11). 4727–4727. 9 indexed citations
18.
Lortholary, Olivier, Jacques Vargaftig, Frédéric Féger, et al.. (2004). Efficacy and Safety of Cladribine in Adult Systemic Mastocytosis : A French Multicenter Study of 33 Patients.. Blood. 104(11). 661–661. 10 indexed citations
19.
Tourneur, Léa, Vincent Lévy, Françoise Valensi, et al.. (2004). Absence or Low Expression of Fas-Associated Protein with Death Domain in Acute Myeloid Leukemia Cells Predicts Resistance to Chemotherapy and Poor Outcome. Cancer Research. 64(21). 8101–8108. 65 indexed citations
20.
Zylberberg, H., Jacques Vargaftig, Claire Barbieux, et al.. (1996). Prolonged Efficiency of Secondary Prophylaxis with Colistin Aerosols for Respiratory Infection Due to Pseudomonas aeruginosa in Patients Infected with Human Immunodeficiency Virus. Clinical Infectious Diseases. 23(3). 641–643. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Wendy Cuccuini Breakdown of academic impact, for papers by Marie Jarošová Breakdown of academic impact, for papers by Alejandra Martínez‐Trillos Breakdown of academic impact, for papers by Claudiu Cotta Breakdown of academic impact, for papers by Florence Armstrong Breakdown of academic impact, for papers by Aleksandra Rizo Breakdown of academic impact, for papers by Takashi Akasaka Breakdown of academic impact, for papers by Beata Holkova Breakdown of academic impact, for papers by Julia Steinhilber Breakdown of academic impact, for papers by K Longin
Rankless by CCL
2026